aTyr Pharma, Inc.ATYRNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank85
3Y CAGR+24.7%
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

3Y CAGR
+24.7%/yr
Annual compound
Percentile
P85
Within normal range
vs 3Y Ago
1.9x
Solid growth
Streak
2 yr
Consecutive growthAccelerating
PeriodValue
202527.73%
20246.15%
20235.63%
202214.29%
202118.47%
2020-2.96%
2019-19.99%
2018-28.57%
201715.30%
20168.25%